NeuroPace, Inc.

NasdaqGM NPCE

NeuroPace, Inc. Free Cash Flow Yield on January 14, 2025: -4.75%

NeuroPace, Inc. Free Cash Flow Yield is -4.75% on January 14, 2025, a 22.17% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

NeuroPace, Inc. 52-week high Free Cash Flow Yield is -4.18% on February 20, 2024, which is 12.04% above the current Free Cash Flow Yield.
NeuroPace, Inc. 52-week low Free Cash Flow Yield is -9.73% on October 23, 2024, which is -104.78% below the current Free Cash Flow Yield.
NeuroPace, Inc. average Free Cash Flow Yield for the last 52 weeks is -6.78%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqGM: NPCE

NeuroPace, Inc.

CEO	Mr. Joel D. Becker
IPO Date	April 22, 2021
Location	United States
Headquarters	455 North Bernardo Avenue
Employees	184
Sector	Health Care
Industries Pharmaceuticals Telehealth Virtual Reality (VR)

Description

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Key trends

Past 5 years